BMS Speeding Six More Programs Into Late-Stage R&D
Registrational Candidates Will Double Over 18 Months
Executive Summary
With big losses of exclusivity later in this decade, Bristol is looking to boost the number of products in its portfolio by 2030 even beyond the $35bn-plus in new revenue it already expects to bring in.
You may also be interested in...
Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First
With a Phase II study stopped for efficacy in bleeding reduction, Anthos hopes to bring abelacimab, a dual Factor XI/XIa inhibitor to market to prevent strokes in a-fib patients and to treat cancer patients with thrombosis.
BMS’s Mezigdomide Myeloma Data Give Glimpse Of CELMoD Future
The trial’s principal investigator said the goal is to establish mezigdomide for use in patients who have failed on Pomalyst. BMS is running a head-to-head trial of both drugs.
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.